|
Originally published In Press as doi:10.1074/jbc.M205326200 on June 26, 2002
J. Biol. Chem., Vol. 277, Issue 36, 32883-32891, September 6, 2002
The Elevation of Glutamate Content and the Amplification of
Insulin Secretion in Glucose-stimulated Pancreatic Islets Are Not
Causally Related*
Gyslaine
Bertrand §,
Nobuyoshi
Ishiyama ,
Myriam
Nenquin ,
Magalie A.
Ravier , and
Jean-Claude
Henquin ¶
From the Unité d'Endocrinologie et
Métabolisme, University of Louvain Faculty of Medicine, B-1200
Brussels, Belgium and the § Unité Propre de Recherche
9023, Centre National de la Recherche Scientifique,
F-34094 Montpellier, France
Received for publication, May 30, 2002
 |
ABSTRACT |
Glucose increases insulin secretion by raising
cytoplasmic Ca2+
([Ca2+]i) in -cells
(triggering pathway) and augmenting the efficacy of Ca2+ on
exocytosis (amplifying pathway). It has been suggested that glutamate
formed from -ketoglutarate is a messenger of the amplifying pathway
(Maechler, P., and Wollheim, C. B. (1999) Nature 402, 685-689). This hypothesis was tested with mouse islets depolarized with 30 mM KCl (+ diazoxide) or with a saturating
concentration of sulfonylurea. Because
[Ca2+]i was elevated under these
conditions, insulin secretion was stimulated already in 0 mM glucose. The amplification of secretion produced
by glucose was accompanied by an increase in islet glutamate. However,
glutamine (0.5-2 mM) markedly augmented islet glutamate without affecting insulin secretion, whereas glucose augmented secretion without influencing glutamate levels when these were elevated
by glutamine. Allosteric activation of glutamate dehydrogenase by BCH
(2-amino 2-norbornane carboxylic acid) lowered islet glutamate but
increased insulin secretion. Similar insulin secretion thus occurred at
very different cellular glutamate levels. Glutamine did not affect
islet [Ca2+]i and
pHi, whereas glucose and BCH slightly raised
pHi and either slightly decreased (30 mM KCl) or increased (tolbutamide)
[Ca2+]i. The general dissociation
between changes in islet glutamate and insulin secretion refutes a role
of -cell glutamate in the amplification of insulin secretion
by glucose.
 |
INTRODUCTION |
Tight control of insulin secretion by pancreatic -cells is
critical for glucose homeostasis. This control is exerted by a number
of physiological agents, among which circulating nutrients, in
particular glucose, play a central role. Glucose regulation of insulin
secretion involves two major signaling pathways leading to the
production of triggering and amplifying signals respectively (1). The
triggering pathway consists in a now well accepted cascade of events.
The metabolism of glucose by oxidative glycolysis causes a rise in the
ATP/ADP ratio, which closes ATP-sensitive K+
(K+-ATP)1
channels. The resulting decrease in K+ conductance leads to
membrane depolarization, with subsequent opening of
voltage-dependent Ca2+ channels,
Ca2+ influx from the extracellular space, and rise in the
concentration of free cytoplasmic Ca2+
([Ca2+]i), which triggers the
exocytosis of insulin granules (2-7). However, the triggering action
of Ca2+ does not completely explain the stimulation of
insulin secretion by glucose. Amplifying signals are also produced in
-cells, and these augment the magnitude of the secretory response,
in particular during the sustained phase of stimulation (8-10).
Whereas the importance of this pathway is now undisputed (1), the
underlying mechanisms remain controversial (1, 11-16).
The present study was prompted by the current controversy surrounding
the hypothesis that intracellular glutamate, formed through amination
of -ketoglutarate by glutamate dehydrogenase (GDH), may serve as
second messenger in this amplifying pathway (17). The hypothesis was
originally based on the observations that glutamate increased insulin
release from permeabilized INS-1 cells perifused with elevated fixed
concentrations of Ca2+ and ATP, that glucose increased
insulinoma and islet cell glutamate content, and that a
membrane-permeant ester of glutamate increased insulin secretion from
intact cells (17). On the other hand, the hypothesis was contradicted
by reports suggesting that glucose does not affect glutamate levels in
islets from ob/ob mice (18, 19) or rats (20) and in
insulinoma cells (15). In addition, the ability of glutamate dimethyl
ester to increase insulin secretion has been attributed to its use as a
nutrient by -cells (21).
Manipulations of the genes coding for glutamate decarboxylase (GAD) and
for GDH have also yielded conflicting results. Overexpression of GAD65
in INS-1E cells increased the enzyme activity 26-fold, lowered cell
glutamate content by ~40%, but inhibited insulin secretion (40%) at
15 mM glucose only, being without effect at 2.5 and 7.5 mM glucose (22). Overexpression of GAD65 in rat islet cells
did not affect insulin secretion in response to 8.3 mM
glucose but inhibited the sustained response to 16.7 mM
glucose (22). These results were considered to support the role of
glutamate in glucose-induced insulin secretion. In contrast, transgenic mice overexpressing GAD65 in -cells, normally released insulin in
response to high glucose; the only defect was an inhibition of first
phase insulin release induced by 7 mM glucose. The study was considered not to support the glutamate hypothesis (23). Overexpression of GDH in INS-1E cells increased human growth hormone release (reporter of insulin release by transfected cells) induced by
high glucose without affecting basal release. It was assumed, not
verified, that the overexpressed enzyme was working in the direction of
-ketoglutarate to glutamate and thus increasing the concentration of
glutamate (24). Conversely, overexpression of a mutated, constitutively
active GDH in MIN6 cells increased insulin release at low glucose
without affecting the response to high glucose. It was now assumed that
the enzyme worked in the opposite direction and thus lowered cell
glutamate content (25).
Glutamine markedly increases islet glutamate content (20, 26, 27) but
does not induce insulin secretion unless GDH is concomitantly activated
by leucine or its non-metabolized analogue BCH (28, 29). This lack of
effect on insulin secretion is explained by the inability of glutamine
alone to produce enough ATP to close K+-ATP channels,
depolarize the membrane, and raise
[Ca2+]i in -cells (26,
29-31).
It would not be correct, however, to use the foregoing data, all
obtained under conditions testing the triggering pathway of insulin
secretion, to refute the glutamate hypothesis, which clearly restricts
the role of glutamate to the amplifying pathway (16). Virtually nothing
has been done to test the hypothesis adequately. Islet glutamate
content has not been measured under conditions where the amplifying
pathway was being studied. Moreover, the available insulin secretion
data are limited to two reports showing that in a medium containing
30-50 mM K+, 250 µM diazoxide,
and no glucose, 10-20 mM glutamine has little or no effect
on insulin secretion, unless, again, if GDH, is activated (9, 32). This
poor effect of glutamine alone has tentatively been ascribed to an
alleged alkalinization of the -cell cytoplasm (16). The explanation
deserves verification because an independent study suggested that
glucose-induced priming of insulin secretion, which is thought to be
mediated by the amplifying pathway (13), is indeed inhibited by
-cell alkalinization (33).
In the present study, mouse islets were thus incubated or perifused
under depolarizing conditions (high K+ or sulfonylurea) to
study the effects of glucose, glutamine, and BCH to activate GDH, on
the amplifying pathway of insulin secretion. Glutamate was measured in
the same islets, and possible changes in
[Ca2+]i and
pHi were checked for in parallel experiments. A
control series of tests was also performed with rat islets to validate
our conclusions in a second species.
 |
EXPERIMENTAL PROCEDURES |
Solutions and Reagents--
The control medium was a
bicarbonate-buffered solution containing (mM): NaCl, 120;
KCl, 4.8; CaCl2, 2.5; MgCl2, 1.2; and
NaHCO3, 24. It was maintained under
O2/CO2 (94:6) to a pH of 7.4, and it contained
10 mM glucose and 1 mg/ml bovine serum albumin. A similar
solution was used as test medium after adjustment of the glucose
concentration and addition of the studied substances. When the
concentration of KCl was increased to 30 mM, that of NaCl
was decreased accordingly; otherwise the substances were added without
osmotic compensation.
Glutamine (Microselect) was from Fluka (Buchs, Switzerland), diazoxide
was a gift of Schering-Plough Avondale (Rathdrum, Ireland), BCH,
tolbutamide, and glibenclamide were from Sigma. Other reagents were from Merck AG (Darmstadt, Germany).
Preparations--
The experiments were performed with
overnight-cultured mouse islets and freshly isolated rat islets. Mouse
islets were aseptically isolated by collagenase digestion of the
pancreas of female NMRI mice (25-30 g) followed by hand selection. The
islets were then cultured for about 18 h in RPMI 1640 medium
containing 10 mM glucose, 10% heat-inactivated fetal calf
serum, 100 IU/ml penicillin, and 100 µg/ml streptomycin. Rat islets
were isolated by collagenase digestion of the pancreas of male Wistar
rats (300-320 g). They were used immediately after isolation.
Measurements of Insulin Secretion and Islet Glutamate
Content--
Cultured mouse islets and freshly isolated rat islets
were preincubated for 60 min at 37 °C in control medium containing
10 mM glucose. They were then distributed in batches of 12, at room temperature, in control medium containing 3 mM
glucose. Each batch was transferred into an Eppendorf conical tube
containing 750 µl of test medium and incubated for 60 min at
37 °C. At the end of the incubation, the tubes were gently (10 s)
centrifuged, 700 µl of medium were removed and saved for insulin
measurement, and 700 µl of cold control medium were added. After
gentle shaking to ensure good rinsing of the islets, the tubes were
again briefly centrifuged, and 700 µl of medium were removed and
discarded. On the islets and the remaining 50 µl of medium, 200 µl
of an acid-ethanol mixture (34) were added. The samples were then sonicated and frozen until glutamate assay. Blanks without islets were
run in parallel and treated exactly as samples.
Cultured mouse islets were also studied using a dynamic system of
perifusion (35). After preincubation as described above and
distribution in batches of 15, the islets were transferred into
perifusion chambers. They were then perifused at 37 °C with test
solutions described in the figure legends. The effluent fractions were
collected at 2-min intervals and saved for insulin assay. At the end of
the experiment the perifusion was stopped, the chamber was opened, and
the islets were recovered, rinsed twice in cold control medium, and
transferred in Eppendorf tubes with 50 µl of medium. After addition
of 200 µl of acid-ethanol mixture, the samples were processed as above.
Measurements of Islet [Ca2+]i and
pHi--
Cultured mouse islets were loaded with the
Ca2+ indicator fura-PE3 (2 µM, 3 h) or
the pH indicator BCECF
(2',7'-bis(2-carboxyethyl)-5(6)-carboxyfluorescein (0.5 µM, 1 h) in control medium containing 10 mM glucose. Loaded islets were then transferred (3-4 at a
time) into the perifusion chamber of a spectrofluorimetric system with
which [Ca2+]i and
pHi were measured as described previously (36,
37).
Insulin and Glutamate Assays--
Insulin in the incubation or
perifusion medium was measured by radioimmunoassay using rat insulin as
a standard. Glutamate in the islet extracts was measured by an high
performance liquid chromatography system (Beckman) using
ortho-phthaldialdehyde (OPA) derivatization. 40 µl of islet extract
were diluted 5-fold with water, mixed with 70 µl of an
OPA-2-mercaptoethanol-derivatizing solution, and injected 1 min later
using a Gilson automatic sample injector (model 231-401) with a fixed
20-min injection cycle. The separation and identification of glutamate
was performed as described previously, with minor modifications (38,
39). The peak area of glutamate was determined with the Gold system
(Beckman), and the glutamate concentration was calculated by comparison
with external standards treated like samples. Only traces or no
glutamate was detected in blanks without islets, except when the
incubation or perifusion medium contained glutamine. All commercial
preparations of glutamine tested contained small quantities of
glutamate. The contamination by exogenous glutamate after rinsing was
about 10% of the islet glutamate content and was corrected for.
Presentation of Results--
All experiments have been performed
with islets from 3-6 different preparations. Results are presented as
means ± S.E. The statistical significance of differences between
means was assessed by analysis of variance followed by a
Newman-Keuls test for multiple comparisons and by Student's
t test in a few cases. Differences were considered
significant at p < 0.05.
 |
RESULTS |
Study of the Amplifying Pathway in Incubated Mouse Islets--
In
the first series of experiments, batches of mouse islets were incubated
with 2 µM glibenclamide, a concentration of sulfonylurea that completely blocks K+-ATP channels (3, 40, 41). Insulin
secretion was stimulated in the absence of glucose (1.39 ± 0.12 ng·h 1·islet 1 versus
0.27 ± 0.02 ng·h 1·islet 1 without
glibenclamide) and was further increased by the presence of 3 mM glucose (2.00 ± 0.28 ng·h 1·islet 1, p < 0.05) and 20 mM glucose (7.41 ± 0.61 ng·h 1·islet 1, p < 0.001) (Fig. 1). This additional effect
of glucose reflects the amplifying action of the sugar (1). The
glutamate content of the islets incubated in 0 mM glucose
and 2 µM glibenclamide averaged 4.67 ± 0.45 pmol·islet 1. It increased 1.4-fold (p < 0.05) and 2.6-fold (p < 0.001) in the presence of 3 and 20 mM glucose, respectively (Fig. 1). Thus, there was a
parallel (but not proportional) increase in islet glutamate content and
insulin secretion under these conditions.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 1.
Insulin secretion and glutamate content in
mouse islets incubated in the presence of a high concentration of
glibenclamide. Batches of 12 mouse islets were incubated in the
presence of 2 µM glibenclamide and 0, 3, or 20 mM glucose (G0, G3, G20).
The medium also contained 0.5 or 2 mM glutamine
(Gln), 10 mM BCH, or the combination of 2 mM Gln and 10 mM BCH as indicated. The results
show the amount of insulin secreted after 1 h of incubation
(open columns) and the glutamate content of the same islets
at the end of the incubation (filled columns). In the
box on top of each panel is given the correlation
coefficient between insulin secretion and the islet glutamate content.
Values are means ± S.E. for 8-11 batches of islets from four
separate preparations. *, p < 0.05 or less
versus controls at the same glucose concentration
(i.e. within each panel). NS, not
significant.
|
|
When glutamine (0.5 and 2 mM) was added to the medium
containing 2 µM glibenclamide, a
concentration-dependent increase in islet glutamate content
was observed (Fig. 1). As compared with control islets, this increase
was particularly large (3- to 5-fold) in 0 and 3 mM
glucose, whereas insulin secretion was at the most doubled by 2 mM glutamine in 3 mM glucose (Fig. 1). There
was no significant effect of glutamine on insulin secretion in the other conditions. For example, the 2-fold increase in glutamate content
induced by 0.5 mM glutamine in 0 or 3 mM
glucose, or by 2 mM glutamine in 20 mM glucose
was not accompanied by significant changes in insulin secretion (Fig.
1). The situation was strikingly different in the presence of BCH, an
activator of glutamate dehydrogenase (28, 42). BCH lowered the islet
glutamate content by about 50% in 0 and 3 mM glucose while
increasing insulin secretion 2-fold (Fig. 1). When BCH and glutamine
were combined, the elevation of islet glutamate normally produced by
glutamine was attenuated, but insulin secretion was amplified except in
20 mM glucose, where BCH lowered islet glutamate without
affecting insulin secretion (Fig. 1).
A second approach to studying the amplifying action of glucose on
insulin secretion consists in holding K+-ATP channels open
with diazoxide and elevating -cell
[Ca2+]i by depolarizing the
membrane with 30 mM K+ (8). Under these
conditions, insulin secretion was stimulated even in the absence of
glucose (2.29 ± 0.17 ng·h 1·islet 1) and was further increased
by 3 mM glucose (3.31 ± 0.25 ng·h 1·islet 1, p < 0.05) and 20 mM glucose (8.26 ± 0.43 ng·h 1·islet 1, p < 0.001) (Fig. 2). The glutamate content of
the islets incubated in 0 mM glucose and 30 mM
K+ averaged 6.15 ± 0.53 pmol·islet 1.
It increased 35% (p < 0.05 by Student's t
test only) and 132% (p < 0.001) in the presence of 3 and 20 mM glucose, respectively (Fig. 2).

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 2.
Insulin secretion and glutamate content in
mouse islets incubated in the presence of a depolarizing concentration
of K+. Batches of 12 mouse islets were incubated in
the presence of 30 mM KCl, 250 µM diazoxide,
and 0, 3, or 20 mM glucose (G0, G3,
G20). The medium also contained 0.5 or 2 mM
glutamine (Gln), 10 mM BCH, or the combination
of 2 mM Gln and 10 mM BCH as indicated. The
results show the amount of insulin secreted after 1 h of
incubation (open columns) and the glutamate content of the
same islets at the end of the incubation (filled columns).
In the box on top of each panel is given the correlation
coefficient between insulin secretion and the islet glutamate content.
Values are means ± S.E. for 10-15 batches of islets from five
separate preparations. *, p < 0.05 or less
versus controls at the same glucose concentration
(i.e. within each panel). NS, not
significant.
|
|
Glutamine consistently elevated islet glutamate content above controls
(from 35% by 0.5 mM glutamine in 20 mM glucose
to 400% by 2 mM glutamine in 0 mM glucose).
However, the only significant effect on insulin secretion was a 50%
increase produced by 2 mM glutamine in 0 mM
glucose (Fig. 2). Again, the contrast with BCH was striking. BCH alone
amplified insulin secretion (50-70%) at 0 and 3 mM
glucose while lowering islet glutamate by 65%. When BCH was combined
with glutamine the rise in islet glutamate was attenuated, but the
increase in insulin secretion was even larger (Fig. 2).
When insulin secretion and the islet glutamate content were compared in
the different experimental conditions tested at each glucose
concentration (each panel of Figs. 1 and 2), no correlation was ever found. However, when the analysis focused on the differences between 0, 3, and 20 mM glucose, a significant correlation
was found for control islets and for islets incubated in the presence of BCH (Fig. 3). There was no correlation
in the presence of 0.5 (Fig. 3) or 2 mM glutamine alone
(not shown). Correlative arguments for and against the glutamate
hypothesis can thus be obtained with this commonly used technique of
incubation. The weakness of the approach is that the correlation is
made between insulin secreted during the whole incubation and the
concentration of an islet metabolite at one single late time point. We
therefore also used a dynamic system of perifusion to permit closer
comparison of the islet glutamate content with the actual rate of
insulin secretion.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 3.
Comparison of the effects of glucose on
insulin secretion and islet glutamate content in incubated mouse
islets. These results, taken from Figs. 1 and 2, were obtained in
the presence of 2 µM glibenclamide (open
symbols) or 30 mM K+ and 250 µM diazoxide (filled symbols) and either no
additional test substance (Controls: , ), 10 mM BCH ( , ) or 0.5 mM glutamine
(Gln: , ). For each symbol, from bottom to top,
the results are in 0, 3, and 20 mM glucose. Values are
means ± S.E.; NS, not significant.
|
|
Study of the Amplifying Pathway in Perifused Mouse Islets--
The
islets were perifused with a medium containing 7 mM glucose
and a concentration of tolbutamide (500 µM) that also
completely blocks K+-ATP channels (3, 40, 41). Under these
conditions the rate of insulin secretion slightly declined with time
(Fig. 4A) but remained well
above (5-7-fold) the basal rate in the presence of 3 mM
glucose alone. Addition of 0.5 mM glutamine to the medium increased the islet glutamate content 2.2-fold without influencing insulin secretion (Fig. 4, A and B). In contrast,
BCH lowered islet glutamate and increased insulin secretion ~4-fold.
The combination of glutamine and BCH increased insulin secretion 5-fold
without changing islet glutamate as compared with controls. Raising the concentration of glucose from 7 to 20 mM also strongly
amplified insulin secretion without changing islet glutamate. Thus,
there was no correlation between islet glutamate content and the actual rate of insulin secretion at the same moment (Fig. 4B).

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 4.
Insulin secretion and glutamate content in
mouse islets perifused in the presence of a high concentration of
tolbutamide. The islets were perifused with a medium containing 7 mM glucose and 500 µM tolbutamide
(G7-Tolb 500 µM). An initial stabilization
period of 40 min is not shown. 10 min after collection of the effluent
fractions was started, a test substance was applied except in the
control group (O). This test substance was a rise of the glucose
concentration to 20 mM (G20), glutamine 0.5 mM (Gln 0.5), BCH 5 mM (BCH
5), or the combination of Gln and BCH. A, actual rates
of insulin secretion in three experimental groups. B,
average rate of insulin secretion computed over the last 10 min
(shaded area in A) and glutamate content of the
same islets removed from the chambers at 80 min. Values are means ± S.E. for eight experiments in which the different protocols were
tested in parallel, with islets from the same preparation. *,
p < 0.05 or less versus controls without
test substance. NS, not significant.
|
|
We also compared the influence of the different test agents on islet
[Ca2+]i and
pHi (Fig. 5).
During continuous depolarization with either a high concentration of
sulfonylurea or a high concentration of extracellular K+,
apparent islet [Ca2+]i slowly but
steadily increases at a rate of approximately 2 nM/min
(43). This trend must be taken into account when assessing possible
effects of test agents. A similar increase was observed in this series
during perifusion of control islets with 7 mM glucose and
500 µM tolbutamide (Fig. 5, A and
B). For all islets tested under these conditions
(n = 65), i.e. during the 5-min period preceding application of test substances, average
[Ca2+]i was 214 ± 2 nM, well above basal
[Ca2+]i in 3 mM
glucose alone (~70-90 nM, data not shown). Glutamine
(0.5 mM) did not affect
[Ca2+]i, whereas BCH alone, BCH
combined with glutamine, and a rise in the glucose concentration to 20 mM all produced similar changes, described previously for
glucose (43) and characterized by a small transient decrease followed
by an increase slightly above control values (Fig. 5, A and
B).

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 5.
Impact of several test agents on
[Ca2+]i and pHi in mouse islets perifused
in the presence of a high concentration of tolbutamide. The islets
were perifused with a medium containing 7 mM glucose and
500 µM tolbutamide (G7-Tolb 500 µM). An initial stabilization period of 20 min is not
shown. 10 min after the recording was started, a test substance was
applied except in the control group. This test substance was a rise of
the glucose concentration to 20 mM (G20), 0.5 mM glutamine (Gln 0.5), 5 mM BCH
(BCH 5), or the combination of Gln and BCH. A and
C, actual changes in
[Ca2+]i and
pHi in control islets (thin lines) or
in test islets (thick lines). B and D,
difference in average [Ca2+]i or
pHi between 40-45 min and 25-30 min
(shaded periods), i.e. during and just before
application of the test substance. Values are means ± S.E. for 13 islets from three preparations for
[Ca2+]i experiments and for 11 islets from three preparations for pHi
experiments. *, p < 0.001 versus controls
without test substance.
|
|
The impact of the same substances on islet pHi
is shown in Fig. 5, C and D. For all islets,
pHi in the presence of 7 mM glucose
and 500 µM tolbutamide, i.e. during the 5-min period before application of any test agent, averaged 6.96 ± 0.01 (n = 55). Addition of glutamine alone had no effect,
whereas BCH (either alone or in combination with glutamine) and high
glucose caused a slight increase in pHi (Fig.
5).
When perifused mouse islets are stimulated with 30 mM
K+ in the presence of 3 mM glucose and
diazoxide, an initial large peak of insulin secretion is followed by a
progressive decline of the secretory rate (9). Only this decline is
shown in Fig. 6. Raising the glucose
concentration to 20 mM stopped this spontaneous evolution and amplified insulin secretion while augmenting islet glutamate levels. Addition of 0.5 or 2 mM glutamine to the medium
failed to influence insulin secretion, although islet glutamate was
increased severalfold. In contrast, BCH alone or combined with 0.5 mM glutamine markedly increased insulin secretion while
lowering islet glutamate content (Fig. 6). Thus, there was no
correlation between islet glutamate and the rate of insulin secretion
at the same moment (Fig. 6).

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 6.
Insulin secretion and glutamate content in
mouse islets perifused in the presence of a depolarizing concentration
of K+. The islets were perifused with a medium
containing 3 mM glucose, 30 mM KCl, and 250 µM diazoxide. An initial period of 30 min is not shown.
10 min after collection of the effluent was started, different test
substances were applied except in the control group (O). These test
substances were a rise of the glucose concentration to 20 mM (G20), 0.5 or 2 mM glutamine
(Gln 0.5, Gln 2), 5 mM BCH (BCH
5), and the combination of BCH and 0.5 mM glutamine
(BCH Gln). A, actual rates of insulin secretion
in three experimental groups. B, average rate of insulin
secretion computed over the last 10 min (shaded area in
A) and glutamate content of the same islets removed from the
chambers at 70 min. Values are means ± S.E. for seven experiments
in which the different protocols were tested in parallel, with islets
from the same preparation. *, p < 0.05 or less
versus controls without test substance. NS, not
significant.
|
|
During steady state depolarization with 30 mM
K+ in the presence of 3 mM glucose and 250 µM diazoxide,
[Ca2+]i was elevated, averaging
286 ± 4 nM for the period of 25-30 min in all islets
(n = 84). As already mentioned above, [Ca2+]i slowly increased with time
under control conditions (Fig. 7).
Raising the concentration of glucose to 20 mM caused a
rapid decrease in [Ca2+]i followed
by an incomplete recovery so that
[Ca2+]i remained below control
values during the period of 40-45 min (Fig. 7, A and
B). A similar biphasic decrease in
[Ca2+]i occurred upon addition of
BCH alone or together with 0.5 mM glutamine. In contrast,
glutamine alone, at 0.5 or 2 mM, was without effect on
[Ca2+]i (Fig. 7, A and
B).

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 7.
Impact of several test agents on
[Ca2+]i and pHi in mouse islets perifused
in the presence of a depolarizing concentration of K+.
The islets were perifused with a medium containing 3 mM
glucose, 30 mM KCl, and 250 µM diazoxide. An
initial stabilization period of 20 min is not shown. 10 min after the
recording was started, a test substance was applied except in the
control group. This test substance was a rise of the glucose
concentration to 20 mM (G20), 0.5 or 2 mM glutamine (Gln 0.5, Gln 2), 5 mM BCH (BCH 5), or the combination of BCH and
0.5 mM glutamine (BCH Gln). A and
C, actual changes in
[Ca2+]i and
pHi in control islets (thin lines)
and in test islets (thick lines). B and
D, differences in average
[Ca2+]i or
pHi between 40-45 min and 25-30 min
(shaded periods), i.e. during and just before
application of the test substance. Values are means ± S.E. for 14 islets from four preparations for
[Ca2+]i experiments and 11 islets
from three preparations for pHi experiments. *,
p < 0.001 versus controls without test
substance.
|
|
In these depolarized islets, pHi averaged
6.87 ± 0.01 (n = 66) during the period of 25-30
min (Fig. 7). Raising the glucose concentration from 3 to 20 mM increased pHi as reported
previously (37). Similar changes were produced by BCH alone and the
combination of BCH and 0.5 mM glutamine, whereas glutamine
alone had no significant effect (Fig. 7, C and
D).
Although 0.5 mM glutamine was generally found
not to amplify insulin secretion, a significant effect was disclosed
when the islets were subjected to the influence of the different test
agents throughout the experiment, and the stimulation with 30 mM K+ was applied after 50 min only (Fig.
8). The initial rate of insulin secretion
was low and independent of the test agent because of the presence of
diazoxide (Fig. 8A). Under these conditions, the presence of
0.5 mM glutamine in the medium containing 3 mM
glucose resulted in a 2-fold increase in K+-induced insulin
secretion, whereas islet glutamate was tripled (Fig. 8, A
and B). However, 10 mM glucose alone tripled
insulin secretion while increasing islet glutamate by 1.5-fold only. At 10 mM glucose, 0.5 mM glutamine doubled islet
glutamate without influencing insulin secretion. Under the same
experimental conditions, BCH lowered glutamate content in 3 mM glucose but did not increase insulin secretion unless it
was combined with exogenous glutamine. In 10 mM glucose the
decrease in islet glutamate induced by BCH had no impact on insulin
secretion (Fig. 8, A and B).

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 8.
Insulin secretion and glutamate content in
mouse islets stimulated by a depolarizing concentration of
K+. The islets were perifused with a medium containing
250 µM diazoxide and either 3 or 10 mM
glucose (G3, G10) throughout. Except in the
control group, the medium also contained 0.5 mM glutamine
(Gln 0.5), 5 mM BCH (BCH 5), or the
combination of Gln and BCH (BCH Gln). An initial
stabilization period of 40 min is not shown. 10 min after collection of
the effluent was started, the concentration of KCl was raised from 4.8 to 30 mM. A, actual rates of insulin secretion
in three experimental groups. B, average rate of insulin
secretion computed over the last 10 min (shaded area in
A) and glutamate content of the same islets removed from the
chambers at 80 min. Values are means ± S.E. for eight experiments
in which the different protocols were tested in parallel, with islets
from the same preparation. *, p < 0.05 or less
versus controls without test substance. NS, not
significant.
|
|
Study of the Amplifying Pathway in Incubated Rat Islets--
It
has been argued that glutamate metabolism and effects might be
different in mouse and rat -cells (16). The potential role of
glutamate in the amplification of insulin secretion was therefore
tested with rat islets during depolarization with 30 mM
K+ in the presence of diazoxide (Fig.
9). K+-induced insulin
secretion in 0 mM glucose amounted to 1.34 ± 0.08 ng·h 1·islet 1. It was increased 45 (p < 0.05) and 310% (p < 0.001) by 3 and 20 mM glucose, respectively. Simultaneously, the islet
glutamate content (7.19 ± 0.34 pmol·islet 1) was
augmented 45 and 95% (p < 0.001), respectively.
Glutamine (2 mM) markedly (4- to 7-fold) elevated islet
glutamate without influencing insulin secretion. In 0 and 3 mM glucose, BCH alone lowered islet glutamate by 35-40%
(p < 0.001 by Student's t test) and
increased insulin secretion. The amplification of insulin secretion was
not significantly larger when BCH was combined with glutamine, although
the islet glutamate content was 5- to 7-fold higher (Fig. 9). In 20 mM glucose, BCH lowered islet glutamate without changing
insulin secretion. These results obtained in rat islets are thus
essentially similar to those in mouse islets, with no correlation
between islet glutamate and insulin secretion.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 9.
Insulin secretion and glutamate content in
rat islets incubated in the presence of a depolarizing concentration of
K+. Batches of 12 rat islets were incubated in the
presence of 30 mM KCl, 250 µM diazoxide, and
0, 3, or 20 mM glucose (G0, G3,
G20). The medium also contained 2 mM glutamine
(Gln), 10 mM BCH, or the combination of 2 mM Gln and 10 mM BCH as indicated. The results
show the amount of insulin secreted after 1 h of incubation
(open columns) and the glutamate content of the same islets
at the end of the incubation (filled columns). In the
box at the top of each panel is given the correlation
coefficient between insulin secretion and the islet glutamate content.
Values are means ± S.E. for 8-11 batches of islets from four
separate preparations. *, p < 0.05 or less
versus controls at the same glucose concentration
(i.e. within each panel). NS, not
significant.
|
|
 |
DISCUSSION |
When the medium did not contain glutamine or BCH, the glutamate
levels of our mouse or rat islets ranged from 5 to 15 pmol·islet 1, i.e. 1.7 to 3 mM
for an intracellular space of 3 nl/islet (26, 44). These values
correspond well with those measured by others in rodent islets (19, 20,
27). They are slightly higher than those in human islets (17) and
INS-1E cells (22) and much higher than those in INS-1 cells (17).
We confirm that glutamine markedly increases islet glutamate levels in
rat islets (20, 26, 27, 45), and we show that it has the same effect in
mouse islets, which can be explained by the activity of the glutaminase
(27). We also establish that activation of GDH by BCH lowers islet
glutamate content not only in the presence of exogenous glutamine (20,
45) but also in its absence. Because this decrease in islet glutamate
by BCH was seen at all glucose concentrations it appears that the flux
controlled by GDH consistently goes from glutamate to
-ketoglutarate. Yet, in contrast with several reports (18-20), we
observed that glucose increased glutamate levels in rat and mouse
islets. This effect was concentration-dependent (~40% at
3 mM and ~120% at 20 mM glucose) but clearly
was less than the 5-fold increase reported for human islets and INS
cells (17). It is also noteworthy that glucose did not affect the
elevation of islet glutamate levels induced by exogenous glutamine but
retained an increasing effect when GDH was activated by BCH, at least
in the mouse.
This study was not designed to investigate the mechanisms by which
glucose might affect glutamate metabolism, but the following explanation is tentatively proposed. The increase in islet glutamate that glucose produces in the absence of glutamine, whether GDH is
activated by BCH or not, may result from an inhibition of GDH by the
high-GTP and low-ADP environment (31, 46) characteristic of
glucose-stimulated islets (47). In the presence of exogenous glutamine,
reduction of the flux through GDH has no impact on the already high
glutamate levels, perhaps because of a decrease in glutaminase activity
(45). This interpretation is fully compatible with recent studies of
leucine-induced insulin secretion in isolated mouse islets (31) and in
patients with an activating mutation of GDH (48).
We emphasize again that our experiments were carried out under
conditions selected to study the amplifying action of glucose and other
agents on insulin secretion. The paradigm is that -cell [Ca2+]i is steadily elevated
independently from the tested agents and is little affected by these
agents (1). Because the latter condition is difficult to achieve direct
control is important, in particular when novel conditions are being
tested. The slight decrease in
[Ca2+]i produced by high glucose
in the presence of high K+ and diazoxide and the small
increase produced in the presence of a maximally effective
concentration of sulfonylurea are similar to those described and
discussed previously (43). This study shows that BCH alone or with
glutamine had a similar or slightly smaller impact on
[Ca2+]i than that of glucose,
whereas glutamine alone did not change
[Ca2+]i. One can thus be confident
that the amplifying pathway of insulin secretion, as opposed to the
triggering pathway that involves a stimulus-induced large increase in
[Ca2+]i from basal values, was
being studied in the present experiments (1). It is also clear that
differences in the effects of the tested agents on insulin secretion
cannot be attributed to markedly divergent actions on
[Ca2+]i.
In agreement with a number of studies reviewed recently (1, 13),
glucose amplified insulin secretion from rat and mouse islets in a
concentration-dependent manner with a significant effect
already at 3 mM. In incubated mouse islets, the
amplification of insulin secretion by glucose was accompanied by an
elevation of islet glutamate content such that a tight, direct
correlation was found between the two variables, both in the absence
and presence of BCH, i.e. at very different glutamate
concentrations. These results, therefore, confirm that insulin
secretion may be directly correlated with cellular glutamate under
selected conditions (22). However, a correlation between a cumulative
event (insulin secretion) and a metabolic situation at a single time
point (islet glutamate concentration) has a limited significance.
Moreover, correlative evidence is never sufficient to establish a
causal link. In fact the arguments against a role of glutamate predominate.
Exogenous glutamine (0.5 and 2 mM) consistently increased
islet glutamate levels, generally to a larger extent than did glucose, but amplified insulin secretion weakly under three conditions only. In
the majority of situations (14/17), glutamine failed to influence
insulin secretion. Importantly, the inefficacy of glutamine on insulin
secretion was observed in the presence of 3 or 7 mM
glucose, i.e. under optimal conditions where metabolism of
the sugar provides basal ATP to sustain Ca2+-induced
exocytosis and where the amplifying pathway is far from being maximally
activated (1). We therefore conclude that a rise in islet glutamate
content is not a sufficient signal to amplify insulin secretion.
In the presence of exogenous glutamine glucose strongly amplified
insulin secretion, although the elevated islet glutamate levels did not
change. We therefore conclude that intracellular glutamate is at best a
permissive signal and that glucose produces one or several other
signals that increase the action of Ca2+ on exocytosis.
Because similar insulin secretion sometimes occurred at very different
intracellular glutamate levels, we can also exclude the remote
possibility that the amplifying action of the amino acid would be
restricted to a narrow range of concentrations.
In the absence of exogenous glutamine, BCH lowered islet glutamate to
below basal values but amplified insulin secretion (0-7 mM
glucose) or did not affect it (10-20 mM glucose).
Combination of BCH and glutamine attenuated the elevation of glutamate
produced by the latter alone but increased or did not affect (in high
glucose) insulin secretion. Changing the glucose concentration from 7 to 20 mM in the presence of tolbutamide also amplified
insulin secretion 3-fold without modifying islet glutamate. We
therefore conclude that an increase in intracellular glutamate is not a
necessary signal for the amplification of insulin secretion.
Exogenous NH4Cl is known to impair the amplification of
insulin secretion by glucose (9). It has therefore been argued that
glutamine is an inadequate tool to test the glutamate hypothesis because NH4 production by the metabolism of the amino acid
in -cells (26) might also blunt the amplifying pathway through an
alkalinization of the cytoplasm or other mechanisms (16). These
concerns are completely ungrounded at least when glutamine is used at a
close to physiological concentration as in this study. First, under no
condition did glutamine impair insulin secretion or impair the
amplification by glucose. Second, we have reported previously that
raising [Ca2+]i in -cells by
high K+ or tolbutamide lowers pHi at
low glucose and that a subsequent rise in glucose or the addition of
-ketoisocaproate (two conditions causing amplification of insulin
secretion) (9), increases pHi (37, 49). We now
show that BCH and the combination of BCH with glutamine produce a
similar alkalinization, whereas glutamine alone has no effect. Our
findings, therefore, contradict the predictions and validate the use of
glutamine to test the hypothesis. Another important observation is that
only those fuels which increase pHi also amplify
insulin secretion. This correlation is clearly insufficient to
establish any causal relationship, but at least it makes untenable the
idea that a decrease in intracellular pH is a major contributor of the
amplifying and related actions of glucose and other nutrients (33).
In conclusion, glucose augments glutamate content in mouse and rat
islets under conditions where the sugar amplifies insulin secretion.
However, this increase is neither sufficient nor necessary. Numerous
dissociations between changes in islet glutamate and insulin secretion
allow us to refute the idea that an increase in -cell glutamate is
an important messenger in the amplification of insulin secretion by glucose.
 |
ACKNOWLEDGEMENTS |
We thank F. Knockaert and R. Puech for
technical assistance and V. Lebec for editorial help.
 |
FOOTNOTES |
*
This work was supported by Grant 3.4552.98 from the Fonds de
la Recherche Scientifique Médicale (Brussels), by Grant ARC 00/05-260 from the General Direction of Scientific Research of the
French Community of Belgium, by the Interuniversity Poles of Attraction
Program P5/3/20 Federal Office for Scientific, Technical, and Cultural
Affairs from Belgium, and by the Centre National de la Recherche
Scientifique (Paris).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Unité
d'Endocrinologie et Métabolisme, UCL 55.30, Ave. Hippocrate 55, B-1200 Brussels, Belgium. Tel.: 32-2-7645529; Fax: 32-2-7645532;
E-mail: henquin@endo.ucl.ac.be.
Published, JBC Papers in Press, June 26, 2002, DOI 10.1074/jbc.M205326200
 |
ABBREVIATIONS |
The abbreviations used are:
K+-ATP
channel, ATP-sensitive K+ channel;
[Ca2+]i, cytoplasmic
Ca2+ concentration;
GDH, glutamate dehydrogenase;
GAD, glutamate decarboxylase;
pHi, cytoplasmic pH;
BCH, 2-amino 2-norbornane carboxylic acid.
 |
REFERENCES |
| 1.
|
Henquin, J. C.
(2000)
Diabetes
49,
1751-1760[Abstract]
|
| 2.
|
Rorsman, P.
(1997)
Diabetologia
40,
487-495[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Ashcroft, F. M.,
and Gribble, F. M.
(1999)
Diabetologia
42,
903-919[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Seino, S.,
Iwanaga, T.,
Nagashima, K.,
and Miki, T.
(2000)
Diabetes
49,
311-318[Abstract]
|
| 5.
|
Newgard, C. B.,
and Matschinsky, F. M.
(2001)
in
Handbook of Physiology
(Jefferson, J.
, and Cherrington, A., eds), Vol. 2
, pp. 125-152, Oxford University Press, London
|
| 6.
|
Schuit, F. C.,
Huypens, P.,
Heimberg, H.,
and Pipeleers, D. G.
(2001)
Diabetes
50,
1-11[Abstract/Free Full Text]
|
| 7.
|
Gilon, P.,
Ravier, M. A.,
Jonas, J. C.,
and Henquin, J. C.
(2002)
Diabetes
51 Suppl. 1,
S144-S151[Abstract/Free Full Text]
|
| 8.
|
Gembal, M.,
Gilon, P.,
and Henquin, J. C.
(1992)
J. Clin. Invest.
89,
1288-1295[Medline]
[Order article via Infotrieve]
|
| 9.
|
Gembal, M.,
Detimary, P.,
Gilon, P.,
Gao, Z. Y.,
and Henquin, J. C.
(1993)
J. Clin. Invest.
91,
871-880[Medline]
[Order article via Infotrieve]
|
| 10.
|
Sato, Y.,
Aizawa, T.,
Komatsu, M.,
Okada, N.,
and Yamada, T.
(1992)
Diabetes
41,
438-443[Abstract]
|
| 11.
|
Sato, Y.,
and Henquin, J. C.
(1998)
Diabetes
47,
1713-1721[Abstract]
|
| 12.
|
Corkey, B. E.,
Deeney, J. T.,
Yaney, G. C.,
Tornheim, K.,
and Prentki, M.
(2000)
J. Nutr.
130,
299S-304S[Abstract/Free Full Text]
|
| 13.
|
Komatsu, M.,
Sato, Y.,
Aizawa, T.,
and Hashizume, K.
(2001)
Endocr. J.
48,
275-288[Medline]
[Order article via Infotrieve]
|
| 14.
|
Eto, K.,
Yamashita, T.,
Tsubamoto, Y.,
Terauchi, Y.,
Hirose, K.,
Kubota, N.,
Yamashita, S.,
Taka, J.,
Satoh, S.,
Sekihara, H.,
Tobe, K.,
Iino, M.,
Noda, M.,
Kimura, S.,
and Kadowaki, T.
(2002)
Diabetes
51,
87-97[Abstract/Free Full Text]
|
| 15.
|
Lu, D.,
Mulder, H.,
Zhao, P.,
Burgess, S. C.,
Jensen, M. V.,
Kamzolova, S.,
Newgard, C. B.,
and Sherry, A. D.
(2002)
Proc. Natl. Acad. Sci. U. S. A.
99,
2708-2713[Abstract/Free Full Text]
|
| 16.
|
Wollheim, C. B.,
and Maechler, P.
(2002)
Diabetes
51 Suppl. 1,
S37-S42[Abstract/Free Full Text]
|
| 17.
|
Maechler, P.,
and Wollheim, C. B.
(1999)
Nature
402,
685-689[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Danielsson, A.,
Hellman, B.,
and Idahl, L. A.
(1970)
Horm. Metab. Res.
2,
28-31[Medline]
[Order article via Infotrieve]
|
| 19.
|
Gylfe, E.,
and Hellman, B.
(1974)
Endocrinology
94,
1150-1156[Abstract/Free Full Text]
|
| 20.
|
MacDonald, M. J.,
and Fahien, L. A.
(2000)
J. Biol. Chem.
275,
34025-34027[Abstract/Free Full Text]
|
| 21.
|
Sener, A.,
Conget, I.,
Rasschaert, J.,
Leclercq-Meyer, V.,
Villanueva- Peñacarrillo, M. L.,
Valverde, I.,
and Malaisse, W. J.
(1994)
Am. J. Physiol.
267,
E573-E584[Abstract/Free Full Text]
|
| 22.
|
Rubi, B.,
Ishihara, H.,
Hegardt, F. G.,
Wollheim, C. B.,
and Maechler, P.
(2001)
J. Biol. Chem.
276,
36391-36396[Abstract/Free Full Text]
|
| 23.
|
Shi, Y.,
Kanaani, J.,
Menard-Rose, V., Ma, Y. H.,
Chang, P. Y.,
Hanahan, D.,
Tobin, A.,
Grodsky, G.,
and Baekkeskov, S.
(2000)
Am. J. Physiol. Endocrinol. Metab.
279,
E684-E694[Abstract/Free Full Text]
|
| 24.
|
Maechler, P.,
Antinozzi, P. A.,
and Wollheim, C. B.
(2000)
IUBMB Life
50,
27-31[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Tanizawa, Y.,
Nakai, K.,
Sasaki, T.,
Anno, T.,
Ohta, Y.,
Inoue, H.,
Matsuo, K.,
Koga, M.,
Furukawa, S.,
and Oka, Y.
(2002)
Diabetes
51,
712-717[Abstract/Free Full Text]
|
| 26.
|
Malaisse, W. J.,
Sener, A.,
Carpinelli, A. R.,
Anjaneyulu, K.,
Lebrun, P.,
Herchuelz, A.,
and Christophe, J.
(1980)
Mol. Cell. Endocrinol.
20,
171-189[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Michalik, M.,
Nelson, J.,
and Erecinska, M.
(1992)
Metabolism
41,
1319-1326[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Sener, A.,
and Malaisse, W. J.
(1980)
Nature
288,
187-189[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Panten, U.,
Zielmann, S.,
Langer, J.,
Zünkler, B. J.,
and Lenzen, S.
(1984)
Biochem. J.
219,
189-196[Medline]
[Order article via Infotrieve]
|
| 30.
| Meissner, H. P., and Henquin, J. C. (1983) Diabetes
1982, ICS 600, Excerpta Medica, pp. 353-360,
Amsterdam
|
| 31.
|
Gao, Z. Y., Li, G.,
Najafi, H.,
Wolf, B. A.,
and Matschinsky, F. M.
(1999)
Diabetes
48,
1535-1542[Abstract]
|
| 32.
|
Yamada, S.,
Komatsu, M.,
Sato, Y.,
Yamauchi, K.,
Aizawa, T.,
and Hashizume, K.
(2001)
Endocr. J.
48,
391-395[Medline]
[Order article via Infotrieve]
|
| 33.
|
Gunawardana, S. C.,
and Sharp, G. W. G.
(2002)
Diabetes
51,
105-113[Abstract/Free Full Text]
|
| 34.
|
Detimary, P.,
Jonas, J. C.,
and Henquin, J. C.
(1995)
J. Clin. Invest.
96,
1738-1745[Medline]
[Order article via Infotrieve]
|
| 35.
|
Henquin, J. C.
(1978)
Nature
271,
271-273[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Gilon, P.,
and Henquin, J. C.
(1992)
J. Biol. Chem.
267,
20713-20720[Abstract/Free Full Text]
|
| 37.
|
Shepherd, R. M.,
and Henquin, J. C.
(1995)
J. Biol. Chem.
270,
7915-7921[Abstract/Free Full Text]
|
| 38.
|
Pin, J. P.,
Weiss, S.,
Sebben, M.,
Kemp, D. E.,
and Bockaert, J.
(1986)
J. Neurochem.
47,
594-603[Medline]
[Order article via Infotrieve]
|
| 39.
|
Bertrand, G.,
Puech, R.,
Loubatieres-Mariani, M. M.,
and Bockaert, J.
(1995)
Am. J. Physiol.
269,
E551-E556[Abstract/Free Full Text]
|
| 40.
|
Zünkler, B. J.,
Lenzen, S.,
Männer, K.,
Panten, U.,
and Trube, G.
(1988)
Arch. Pharmacol.
337,
225-230
|
| 41.
|
Aguilar-Bryan, L.,
Clement, J. P.,
Gonzalez, G.,
Kunjilwar, K.,
Babenko, A.,
and Bryan, J.
(1998)
Physiol. Rev.
78,
227-245[Abstract/Free Full Text]
|
| 42.
|
Panten, U.,
and Langer, J.
(1981)
Biochem. J.
198,
353-356[Medline]
[Order article via Infotrieve]
|
| 43.
|
Sato, Y.,
Anello, M.,
and Henquin, J. C.
(1999)
Endocrinology
140,
2252-2257[Abstract/Free Full Text]
|
| 44.
|
Meglasson, M. D.,
and Matschinsky, F. M.
(1986)
Diabetes Metab. Rev.
2,
163-214[Medline]
[Order article via Infotrieve]
|
| 45.
|
Malaisse-Lagae, F.,
Sener, A.,
Garcia-Morales, P.,
Valverde, I.,
and Malaisse, W. J.
(1982)
J. Biol. Chem.
257,
3754-3758[Abstract/Free Full Text]
|
| 46.
|
Stanley, C. A.,
Fang, J.,
Kutyna, K.,
Hsu, B. Y. L.,
Ming, J. E.,
Glaser, B.,
and Poncz, M.
(2000)
Diabetes
49,
667-673[Abstract]
|
| 47.
|
Detimary, P.,
Van Den Berghe, G.,
and Henquin, J. C.
(1996)
J. Biol. Chem.
271,
20559-20565[Abstract/Free Full Text]
|
| 48.
|
Kelly, A., Ng, D.,
Ferry, R. J., Jr.,
Grimberg, A.,
Koo-Mccoy, S.,
Thornton, P. S.,
and Stanley, C. A.
(2001)
J. Clin. Endocrinol. Metab.
86,
3724-3728[Abstract/Free Full Text]
|
| 49.
|
Shepherd, R. M.,
Gilon, P.,
and Henquin, J. C.
(1996)
Endocrinology
137,
677-685[Abstract]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
C. Broca, J. Quoyer, S. Costes, N. Linck, A. Varrault, P.-M. Deffayet, J. Bockaert, S. Dalle, and G. Bertrand
{beta}-Arrestin 1 Is Required for PAC1 Receptor-mediated Potentiation of Long-lasting ERK1/2 Activation by Glucose in Pancreatic {beta}-Cells
J. Biol. Chem.,
February 13, 2009;
284(7):
4332 - 4342.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. V. Jensen, J. W. Joseph, S. M. Ronnebaum, S. C. Burgess, A. D. Sherry, and C. B. Newgard
Metabolic cycling in control of glucose-stimulated insulin secretion
Am J Physiol Endocrinol Metab,
December 1, 2008;
295(6):
E1287 - E1297.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Stiernet, M. Nenquin, P. Moulin, J.-C. Jonas, and J.-C. Henquin
Glucose-induced Cytosolic pH Changes in beta-Cells and Insulin Secretion Are Not Causally Related: STUDIES IN ISLETS LACKING THE NA+/H+ EXCHANGER NHE1
J. Biol. Chem.,
August 24, 2007;
282(34):
24538 - 24546.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Noriega-Lopez, A. R. Tovar, M. Gonzalez-Granillo, R. Hernandez-Pando, B. Escalante, P. Santillan-Doherty, and N. Torres
Pancreatic Insulin Secretion in Rats Fed a Soy Protein High Fat Diet Depends on the Interaction between the Amino Acid Pattern and Isoflavones
J. Biol. Chem.,
July 13, 2007;
282(28):
20657 - 20666.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. M. Doliba, S. L. Wehrli, M. Z. Vatamaniuk, W. Qin, C. W. Buettger, H. W. Collins, and F. M. Matschinsky
Metabolic and ionic coupling factors in amino acid-stimulated insulin release in pancreatic beta-HC9 cells
Am J Physiol Endocrinol Metab,
June 1, 2007;
292(6):
E1507 - E1519.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Moulin, Y. Guiot, J.-C. Jonas, J. Rahier, O. Devuyst, and J.-C. Henquin
Identification and subcellular localization of the Na+/H+ exchanger and a novel related protein in the endocrine pancreas and adrenal medulla
J. Mol. Endocrinol.,
March 1, 2007;
38(3):
409 - 422.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. O. Westermark, J. H. Kotaleski, A. Bjorklund, V. Grill, and A. Lansner
A mathematical model of the mitochondrial NADH shuttles and anaplerosis in the pancreatic beta-cell
Am J Physiol Endocrinol Metab,
February 1, 2007;
292(2):
E373 - E393.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-C. Henquin, D. Dufrane, and M. Nenquin
Nutrient Control of Insulin Secretion in Isolated Normal Human Islets
Diabetes,
December 1, 2006;
55(12):
3470 - 3477.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Newsholme, L. Brennan, and K. Bender
Amino Acid Metabolism, {beta}-Cell Function, and Diabetes
Diabetes,
December 1, 2006;
55(Supplement_2):
S39 - S47.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Corless, A. Kiely, N. H McClenaghan, P. R Flatt, and P. Newsholme
Glutamine regulates expression of key transcription factor, signal transduction, metabolic gene, and protein expression in a clonal pancreatic {beta}-cell line.
J. Endocrinol.,
September 1, 2006;
190(3):
719 - 727.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. V. Jensen, J. W. Joseph, O. Ilkayeva, S. Burgess, D. Lu, S. M. Ronnebaum, M. Odegaard, T. C. Becker, A. D. Sherry, and C. B. Newgard
Compensatory Responses to Pyruvate Carboxylase Suppression in Islet beta-Cells: PRESERVATION OF GLUCOSE-STIMULATED INSULIN SECRETION
J. Biol. Chem.,
August 4, 2006;
281(31):
22342 - 22351.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Wiederkehr and C. B. Wollheim
Minireview: Implication of Mitochondria in Insulin Secretion and Action
Endocrinology,
June 1, 2006;
147(6):
2643 - 2649.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Ishiyama, M. A. Ravier, and J.-C. Henquin
Dual mechanism of the potentiation by glucose of insulin secretion induced by arginine and tolbutamide in mouse islets
Am J Physiol Endocrinol Metab,
March 1, 2006;
290(3):
E540 - E549.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. J. Marx and W. F. Simonds
Hereditary Hormone Excess: Genes, Molecular Pathways, and Syndromes
Endocr. Rev.,
August 1, 2005;
26(5):
615 - 661.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. E. Rabaglia, M. P. Gray-Keller, B. L. Frey, M. R. Shortreed, L. M. Smith, and A. D. Attie
{alpha}-Ketoisocaproate-induced hypersecretion of insulin by islets from diabetes-susceptible mice
Am J Physiol Endocrinol Metab,
August 1, 2005;
289(2):
E218 - E224.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Thams, M. R Anwar, and K. Capito
Glucose triggers protein kinase A-dependent insulin secretion in mouse pancreatic islets through activation of the K+ATP channel-dependent pathway
Eur. J. Endocrinol.,
April 1, 2005;
152(4):
671 - 677.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. MacDonald, L. A. Fahien, L. J. Brown, N. M. Hasan, J. D. Buss, and M. A. Kendrick
Perspective: emerging evidence for signaling roles of mitochondrial anaplerotic products in insulin secretion
Am J Physiol Endocrinol Metab,
January 1, 2005;
288(1):
E1 - E15.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Nenquin, A. Szollosi, L. Aguilar-Bryan, J. Bryan, and J.-C. Henquin
Both Triggering and Amplifying Pathways Contribute to Fuel-induced Insulin Secretion in the Absence of Sulfonylurea Receptor-1 in Pancreatic {beta}-Cells
J. Biol. Chem.,
July 30, 2004;
279(31):
32316 - 32324.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Li, C. Buettger, J. Kwagh, A. Matter, Y. Daikhin, I. B. Nissim, H. W. Collins, M. Yudkoff, C. A. Stanley, and F. M. Matschinsky
A Signaling Role of Glutamine in Insulin Secretion
J. Biol. Chem.,
April 2, 2004;
279(14):
13393 - 13401.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Anno, S. Uehara, H. Katagiri, Y. Ohta, K. Ueda, H. Mizuguchi, Y. Moriyama, Y. Oka, and Y. Tanizawa
Overexpression of constitutively activated glutamate dehydrogenase induces insulin secretion through enhanced glutamate oxidation
Am J Physiol Endocrinol Metab,
February 1, 2004;
286(2):
E280 - E285.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Yamada, M. Komatsu, Y. Sato, K. Yamauchi, T. Aizawa, and I. Kojima
Nutrient Modulation of Palmitoylated 24-Kilodalton Protein in Rat Pancreatic Islets
Endocrinology,
December 1, 2003;
144(12):
5232 - 5241.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-J. Liu, H. Cheng, H. Drought, M. J. MacDonald, G. W. G. Sharp, and S. G. Straub
Activation of the KATP channel-independent signaling pathway by the nonhydrolyzable analog of leucine, BCH
Am J Physiol Endocrinol Metab,
August 1, 2003;
285(2):
E380 - E389.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Li, H. Najafi, Y. Daikhin, I. B. Nissim, H. W. Collins, M. Yudkoff, F. M. Matschinsky, and C. A. Stanley
Regulation of Leucine-stimulated Insulin Secretion and Glutamine Metabolism in Isolated Rat Islets
J. Biol. Chem.,
January 24, 2003;
278(5):
2853 - 2858.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|